Filing Flows › Castle Biosciences (CSTL) › Q3 2026
Castle Biosciences (CSTL) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
Castle Biosciences (CSTL) reported revenue of $103M for the third quarter 2026 (Q3 2026), +24% from a year earlier and -0.6% from the quarter before. Operating margin was -2.7%, net loss $4.1M (4.0% of revenue).
Castle Biosciences, Q3 2026: revenue $103M (+24% year over year), operating margin -2.7%, net loss $4.1M, operating cash flow $19.7M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $103M | -0.6% | +24% |
| Operating profit | −$2.7M | — | — |
| Net earnings | −$4.1M | — | — |
| Operating cash flow | $19.7M | +30% | -13% |
| Free cash flow | $12.2M | +87% | +57% |
What changed
Revenue was $102.9M in Q3 2026, up 24% year over year and down 1% from the previous quarter. Non-Dermatologic was the largest line at 53% of revenue. Non-Dermatologic added $20.5M year over year (up 59%), 103% of the total change. Dermatologic declined 1%.
Operating costs exceeded revenue by $2.7M, an operating margin of -2.7%. Total costs grew 18% against revenue growth of 24%. The fastest-growing cost line was Cost of revenue (+28%). The quarter ended with a net loss of $4.1M, wider than the previous quarter's $2.1M loss.
Operating cash flow was $19.7M (down 13% year over year). Non-cash charges added back $4.2M of depreciation and amortization and $11.2M of share-based compensation. Working capital and other items added $8.4M. Capital expenditures of $7.5M left free cash flow of $12.2M.
Questions
What was Castle Biosciences' revenue in the third quarter 2026?
Castle Biosciences (CSTL) reported revenue of $103M for the third quarter 2026 (Q3 2026), +24% from a year earlier and -0.6% from the quarter before.
Was Castle Biosciences profitable in the third quarter 2026?
Operating loss was $2.7M (-2.7% of revenue) and net loss $4.1M.
Source: Castle Biosciences 10-Q on SEC EDGAR.